{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:24:36Z","timestamp":1787225076116,"version":"build-2736575974"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>For most of the twentieth century, the transcriptional output of the human genome was thought to be biologically inert\u2014a characterization that has been proven wrong in almost every important respect. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar RNAs (snoRNAs) and PIWI-interacting RNAs (piRNAs) are now thought of as vital regulators of gene expression in all the stages of cancer pathogenesis, including the initial epigenetic changes, metastatic spread and the development of therapeutic resistance. This review highlights four areas where the clinical potential of ncRNAs is most promising: reconstruction of ncRNA regulatory networks by multi-omics integration; circulating ncRNAs as minimally invasive cancer biomarkers; causal roles of ncRNAs in drug resistance through epithelial-mesenchymal plasticity, metabolic reprogramming, and stromal communication; and translation of ncRNA targeting strategies to clinical trials. We will need to invest equally in mechanistic rigor and translational infrastructure to move forward.<\/jats:p>","DOI":"10.3389\/fonc.2026.1924660","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:36:44Z","timestamp":1787222204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-coding RNAs in cancer: multi-omics insights, liquid biopsy advances, drug resistance mechanisms, and the road to clinical translation"],"prefix":"10.3389","volume":"16","author":[{"given":"\u015eeyma","family":"Tutar","sequence":"first","affiliation":[{"name":"Division of Biochemistry, Faculty of Medicine, Recep Tayyip Erdogan University","place":["Rize, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vida","family":"Rezayifar","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry, Faculty of Medicine, Recep Tayyip Erdo\u011fan University","place":["Rize, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamida Abakar Mohamed","family":"Elhaj","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Faculty of Medicine, Recep Tayyip Erdogan University","place":["Rize, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Tutar","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Mathematics and Natural Sciences, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cennet","family":"Ataman","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory (Food Analysis Department), Lifeprint GmbH","place":["Illertissen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00fctfi","family":"Tutar","sequence":"additional","affiliation":[{"name":"Departmant of Molecular Biology and Genetics, Faculty of Science and Letters, K\u0131r\u015fehir Ahi Evran University","place":["K\u0131r\u015fehir, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","year":"2012","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1186\/s12967-024-05554-4","article-title":"A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer","volume":"22","author":"Grillone","year":"2024","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00709","article-title":"RNA interference nanotherapeutics for treatment of glioblastoma multiforme","volume":"17","author":"Singh","year":"2020","journal-title":"Mol Pharm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14300","article-title":"Applications of engineered exosomes in drugging noncoding RNAs for cancer therapy","volume":"102","author":"Alemi","year":"2023","journal-title":"Chem Biol Drug Des"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155329","article-title":"From oncogenes to tumor suppressors: The dual role of ncRNAs in fibrosarcoma","volume":"258","author":"Kazmi","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.113744","article-title":"Exosome-based smart drug delivery for cancer treatment","author":"Malik","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.03.003","article-title":"The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics","volume":"20","author":"Bautista-S\u00e1nchez","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.102123","article-title":"Decoding the promise and challenges of miRNA-based cancer therapies: An essential update on miR-21, miR-34, and miR-155","volume":"21","author":"Qian","year":"2024","journal-title":"Int J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/genes13081401","article-title":"The methylation of the p53 targets the genes MIR-203, MIR-129-2, MIR-34A and MIR-34B\/C in the tumor tissue of diffuse large B-cell lymphoma","volume":"13","author":"Voropaeva","year":"2022","journal-title":"Genes (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-022-00903-7","article-title":"Tumor suppressor LHPP suppresses cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cell lines","volume":"78","author":"Ma","year":"2022","journal-title":"J Physiol Biochem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2016.06.06","article-title":"Long non-coding RNA HOTAIR expression in diffuse large B-cell lymphoma: In relation to polycomb repressive complex pathway proteins and H3K27 trimethylation","volume":"50","author":"Oh","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/bi401085h","article-title":"Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins","volume":"52","author":"Wu","year":"2013","journal-title":"Biochemistry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncrna.2025.01.004","article-title":"Long non-coding RNAs in humans: Classification, genomic organization and function","volume":"11","author":"Chodurska","year":"2025","journal-title":"Non-coding RNA Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1748441","article-title":"MALAT1 rs619586 as a potential genetic marker of pituitary adenoma susceptibility and aggressiveness","volume":"17","author":"Juskiene","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1807953","article-title":"A ferroptosis-related lncRNAs risk score model identifies LINC02178 as a potential regulator of ferroptosis sensitivity in cervical cancer","volume":"16","author":"Chen","year":"2026","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1261\/rna.078916.121","article-title":"SnoRNA guide activities: real and ambiguous","volume":"27","author":"Deryusheva","year":"2021","journal-title":"RNA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/genes17050581","article-title":"Systematic identification of immune-related snoRNAs: Potential dual roles in tumor progression and immunotherapy response","volume":"17","author":"Li","year":"2026","journal-title":"Genes (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00587","article-title":"Small nucleolar RNAs: Insight into their function in cancer","volume":"9","author":"Liang","year":"2019","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639763","article-title":"Small non-coding RNAs: key regulatory factors and potential therapeutic targets in tumor immunity","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108049","article-title":"The role of Chinese medicines in targeting non-coding RNAs to overcome cancer drug resistance: Mechanisms and clinical translation challenges","volume":"222","author":"Chen","year":"2025","journal-title":"Pharmacol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-024-00563-3","article-title":"Critical appraisal of the piRNA-PIWI axis in cancer and cancer stem cells","volume":"12","author":"Garcia-Borja","year":"2024","journal-title":"biomark Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/genes16070722","article-title":"piRNA-mediated maintenance of genome stability in gametogenesis and cancer","volume":"16","author":"Zawalska","year":"2025","journal-title":"Genes (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12943-019-1052-9","article-title":"The emerging role of the piRNA\/piwi complex in cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pr9071208","article-title":"The regulation and role of piRNAs and PIWI proteins in cancer","volume":"9","author":"Jeong","year":"2021","journal-title":"Processes"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01086-1","article-title":"Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential","volume":"48","author":"Han","year":"2025","journal-title":"Cell Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12864-016-2457-0","article-title":"Integrating RNA-seq and ChIP-seq data to characterize long non-coding RNAs in Drosophila melanogaster","volume":"17","author":"Chen","year":"2016","journal-title":"BMC Genomics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.761700","article-title":"Cancer CRC: A comprehensive cancer core transcriptional regulatory circuit resource and analysis platform","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1038\/s41467-020-14743-w","article-title":"An integrative ENCODE resource for cancer genomics","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1039\/D5MD00867K","article-title":"Recent progress of METTL3 inhibitors for cancer therapeutics: design, optimization and potential applications","volume":"17","author":"Zhang","year":"2026","journal-title":"RSC Med Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1681555","article-title":"The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy","volume":"13","author":"Ramalingam","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11739","article-title":"N6-methyladenine RNA modification and cancer (Review)","volume":"20","author":"Yang","year":"2020","journal-title":"Oncol Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1749911","article-title":"Rewriting the RNA code: an m6a-centric framework to classify tumors and guide combination therapies","volume":"17","author":"Sun","year":"2026","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222509110","article-title":"Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments","volume":"110","author":"Ala","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler","year":"2014","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/896206","article-title":"Competing endogenous RNA: The key to posttranscriptional regulation","volume":"2014","author":"Sen","year":"2014","journal-title":"Sci World J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205060","article-title":"Current technologies for RNA-directed liquid diagnostics","volume":"13","author":"Martinez-Dominguez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.05.011","article-title":"Methodological considerations for circulating long noncoding RNA quantification","volume":"28","author":"de Gonzalo-Calvo","year":"2022","journal-title":"Trends Mol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2019.07.001","article-title":"Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner","volume":"117","author":"Wang","year":"2019","journal-title":"TrAC Trends Anal Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.64336\/001c.154816","article-title":"Circulating lncRNA biomarker variability in early cancer detection: Implications of standardization and SUMOylation-associated extracellular vesicle packaging","volume":"9","author":"Ramesh","year":"2025","journal-title":"J High School Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618967","article-title":"Circulating serum exosomal long non-coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as diagnostic biomarkers for colorectal cancer","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071081","article-title":"Insights on the biomarker potential of exosomal non-coding RNAs in colorectal cancer: An in silico characterization of related exosomal lncRNA\/circRNA\u2013miRNA\u2013target axis","volume":"12","author":"Mezher","year":"2023","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333522","article-title":"Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study","volume":"74","author":"Cai","year":"2025","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2748","article-title":"Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652\u20133p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer","volume":"30","author":"Hedayat","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells14221750","article-title":"Exosome-mediated crosstalk between cancer cells and tumor microenvironment","volume":"14","author":"Saad","year":"2025","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1451003","article-title":"Extracellular vesicles & Co.: scaring immune cells in the TME since ever","volume":"15","author":"Rodolfo","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12967-025-06629-6","article-title":"Unraveling the advances of non-coding RNAs on the tumor microenvironment: innovative strategies for cancer therapies","volume":"23","author":"Mu","year":"2025","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.02.007","article-title":"LncRNA Neat1 promotes the macrophage inflammatory response and acts as a therapeutic target in titanium particle-induced osteolysis","volume":"142","author":"Lin","year":"2022","journal-title":"Acta Biomater"},{"key":"B52","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The role of non-coding RNAs in oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1378302","article-title":"The hidden messengers: cancer associated fibroblasts\u2014derived exosomal miRNAs as key regulators of cancer Malignancy","volume":"12","author":"Gou","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1833649","article-title":"miR-2110 orchestrates ERK\u2013ELK1 transcriptional repression to induce cell-cycle arrest and enhance cytarabine sensitivity in acute myeloid leukemia","volume":"16","author":"Li","year":"2026","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"eabb3945","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference\u2013based spherical nucleic acids in patients with recurrent glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113130","article-title":"Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ib\/IIa study","volume":"12","author":"Schultheis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent Malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1924660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:36:45Z","timestamp":1787222205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1924660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1924660"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1924660","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1924660"}}